Helping Cancer Patients with Chronic Pain
Creating Ethical Shareholder Value
Business Strategy
Market potential, Real World Evidence & Changing Perspectives.
Helping Cancer Patients with Chronic Pain
CBD Science Group PLC has identified this unmet medical need and have initiated Real World Evidence (RWE) clinical trials.
3,000,000 people are currently suffering from cancer in the UK
1000 patients diagnosed daily
33% of those who suffer from pain associated with cancer are undertreated
Creating Shareholder Value
Every 1000 patients treated has the potential to generate £3.6 million in annual revenue for CBD Science Group PLC. Comparable companies are trading at 10 to 40 times revenue.
Market Potential
Total Medicinal Cannabis Market Value forecasted at £7.7 Billion by 2028
GW Pharma, the largest UK based cannabinoid company, as a comparable and recently sold for over £5 billion
Over 50% of adults reported that they had a pain condition.
RWE
Why Real-World Evidence?
Patient Solutions
Reimbursement Decisions
Regulatory Decisions
Changing Perspectives
Too often UK patients are self-medicating, with illegal cannabis-based products simply the pathway to a legal, medical-cannabis prescription is so unclear and inaccessible. This must change for those in need.
Only 5% of surveyed respondents would not consider using Cannabis Based Medicines.
